Morgan Stanley lowered the firm’s price target on Maravai Lifesciences (MRVI) to $5 from $7 and keeps an Equal Weight rating on the shares. Following a “mixed” Q4, the firm maintains an Equal Weight rating pending evidence of sustained top-line recovery despite the stock’s pullback, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Earnings Call: Growth Amid Challenges
- Biotech Alert: Searches spiking for these stocks today
- Strategic Acquisitions and Market Expansion Drive Buy Rating for Maravai Lifesciences Holdings
- Maravai Lifesciences price target lowered to $5 from $10 at Stifel
- Maravai Lifesciences Projects 2025 Revenue and Expenses